

2021 Onco-Nephrology Symposium

October 8-9, 2021

Schedule reflects Central Time Zone (CT)

Friday, October 8, 2021

12:55 p.m. **Welcome and Course overview**

Kidney disorders in cancer patients

Moderators: Iasmina M. Craici, M.D.
Sandhya Manohar, M.B.B.S.

1:00 p.m. **Acute kidney injury in patients with malignancy**
Abhijat Kitchlu, M.D.

1:30 p.m. **Electrolyte disorders in malignancy**
Sheron Latcha, M.D.

2:00 p.m. **Nephrotoxicity of chemotherapeutic agents**
Kenar Dinesh Jhaveri, M.D.

2:30 p.m. **Dosing of chemotherapy in patients with CKD/ESRD**
Heidi D. Finnes, Pharm.D., R.Ph.

3:00 p.m. **Panel Q&A Session**

3:15 p.m. **BREAK**

Monoclonal gammopathy and the kidney

Moderators: Nelson Leung, M.D.
Mireille El Ters, M.D.

3:30 p.m. **Renal pathology of Myeloma and MGRS related diseases**
Samih H. Nasr, M.D.

4:00 p.m. **Management of Cast nephropathy and MGRS related diseases**
Nelson Leung, M.D.

4:30 p.m. **Kidney transplantation in multiple myeloma and MGRS**
Andrea I. Havasi, M.D.

5:00 p.m. **Panel Q&A Session**

5:15 p.m. **ADJOURN**

Saturday, October 9, 2021

7:55 a.m. **Announcements**

Special session on Overcoming the nephrotoxicity of check point inhibitors

Moderators: Maria (Lourdes) Gonzalez Suarez, M.D., Ph.D.
Lisa Kottschade, APRN, C.N.P.

8:00 a.m. **The use of check point inhibitors in cancer**
Svetomir N. Markovic, M.D., Ph.D.

8:30 a.m. **Pathology of check point inhibitor nephrotoxicity**
Miriam (Priya) P. Alexander, M.D.

9:00 a.m. **Overcoming nephrotoxicity of check point inhibitors**
Sandra M. Herrmann, M.D.

9:30 a.m. **Panel Q&A Session**

9:45 a.m. **BREAK**

Novel hematologic and oncologic treatments and their effects on the kidney

Moderators: Yi Lin, M.D., Ph.D.
Sandra M. Herrmann, M.D.

10:00 a.m. **Car-T cell therapy and cytokine release syndrome**
Yi Lin, M.D., Ph.D.

10:30 a.m. **Hematopoietic stem cell transplantation and the kidney**
Ala Abudayyeh, M.D.

11:00 a.m. **Update on the treatment of renal cell carcinoma**
Brian A. Costello, M.D.

11:30 a.m. **Peptide receptor radionuclide therapy (PRRT) in chronic kidney disease patients**
Sandhya Manohar, M.B.B.S.

12:00 p.m. **Panel Q&A Session**

12:15 p.m. **ADJOURN**